deltatrials
Unknown OBSERVATIONAL NCT05456074

Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR) (IMCOR)

Sponsor: Institut de cancérologie Strasbourg Europe

Conditions Renal Carcinoma
Interventions Data collection
Updated 5 times since 2022 Last updated: Nov 23, 2022 Started: Jan 25, 2023 Primary completion: Jan 25, 2026 Completion: Jan 25, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Renal Carcinoma, this trial is ongoing. The trial is conducted by Institut de cancérologie Strasbourg Europe and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshotNot Yet Recruiting~Feb 2026 – present · 7 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown

    Status: Not Yet Recruiting → Unknown

  2. Sep 2024 — Feb 2026 [monthly]

    Not Yet Recruiting

  3. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting

  4. Dec 2022 — Jul 2024 [monthly]

    Not Yet Recruiting

  5. Sep 2022 — Dec 2022 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut de cancérologie Strasbourg Europe
  • Ministry of Health, France
  • National Cancer Institute, France
Data source: Institut de cancérologie Strasbourg Europe

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations